AI-assisted, human-published
04/21/2025 /M & A
Jazz Pharmaceuticals Acquires Chimerix, Adding Potential Therapy to Oncology Portfolio
Jazz Pharmaceuticals has completed the acquisition of Chimerix, Inc. for $935 million, adding a potential therapy for H3 K27M-mutant diffuse glioma to its oncology portfolio.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com